Application of CMKLR1 micromolecule antagonist to control nonalcoholic fatty liver and hepatitis
A non-alcoholic, antagonistic technology, applied in the direction of anti-inflammatory agents, amine active ingredients, non-central analgesics, etc., can solve the problems of long time and achieve low cost, good market application prospects, and simple synthesis
Inactive Publication Date: 2015-03-25
SHENZHEN INST OF ADVANCED TECH
View PDF1 Cites 27 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
but it takes a long time
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0030] Application of CMKLR1 small molecule antagonist in preventing and treating non-alcoholic fatty liver and hepatitis; the CMKLR1 small molecule antagonist is α-NETA and its derivatives.
[0031] The non-alcoholic fatty liver and hepatitis are fatty liver and hepatitis caused by high energy diet.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The invention discloses application of a CMKLR1 micromolecule antagonist to control nonalcoholic fatty liver and hepatitis. The application of the CMKLR1 micromolecule antagonist to control nonalcoholic fatty liver and hepatitis is proved according to the following steps: employing alpha-NETA with different concentration to intervene a nonalcoholic fatty liver in-vitro model, and performing result detection; and employing alpha-NETA with a quantitative concentration to intervene a nonalcoholic fatty liver in-vivo model, detecting acquired tissue. The CMKLR1 micromolecule antagonist is capable of specifically antagonizing GPCR receptor ChemR23, and provides a new tool for medicines treating nonalcoholic fatty liver or fatty liver hepatitis. The CMKLR1 micromolecule antagonist is relatively simple in synthesis and relatively low in cost, and has extremely good market application prospect on control of nonalcoholic fatty liver and hepatitis.
Description
【Technical field】 [0001] The invention belongs to the technical field of biomedicine, and particularly relates to the application of CMKLR1 small molecule antagonist in preventing and treating non-alcoholic fatty liver and hepatitis. 【Background technique】 [0002] With the growth of social economy and the continuous improvement of diet structure and living standards, metabolic syndrome caused by excessive dietary nutrition is also increasing. Metabolic syndrome refers to a group of diseases related to metabolic disorders caused by excess energy in the body. Its three major energy-producing substances cannot effectively generate energy and cause excessive storage, such as excessive sugar conversion into glycogen or fat, resulting in cell storage pools Saturation, then insulin resistance and diabetes appear; when the lipid storage is in a saturated state, obesity, fatty liver and cholesterol-related diseases, such as coronary heart disease and atherosclerosis, will appear. A...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K31/14A61P1/16A61P29/00
CPCA61K31/14
Inventor 张键穆淑花张旭
Owner SHENZHEN INST OF ADVANCED TECH
Features
- Generate Ideas
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com